In a filing, Protagonist Therapeutics Inc revealed its Chief Medical Officer MOLINA ARTURO MD unloaded Company’s shares for reported $78108.0 on Nov 15 ’24. In the deal valued at $40.98 per share,1,906 shares were sold. As a result of this transaction, MOLINA ARTURO MD now holds 46,444 shares worth roughly $1.8 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Ali Asif sold 14,203 shares, generating $631,872 in total proceeds. Upon selling the shares at $44.49, the Chief Financial Officer now owns 34,960 shares.
Before that, Waddill William D. sold 8,000 shares. Protagonist Therapeutics Inc shares valued at $360,000 were divested by the Director at a price of $45.00 per share. As a result of the transaction, Waddill William D. now holds 12,000 shares, worth roughly $0.46 million.
Wedbush initiated its Protagonist Therapeutics Inc [PTGX] rating to an Outperform in a research note published on November 05, 2024; the price target was $58. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. Truist began covering PTGX with “Buy” recommendation on September 09, 2024. CapitalOne started covering the stock on October 30, 2023. It rated PTGX as “an Overweight”.
Price Performance Review of PTGX
On Tuesday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -4.31% to $38.65. Over the last five days, the stock has lost -10.47%. Protagonist Therapeutics Inc shares have risen nearly 68.56% since the year began. Nevertheless, the stocks have risen 129.92% over the past one year. While a 52-week high of $48.89 was reached on 10/28/24, a 52-week low of $16.63 was recorded on 01/05/24. SMA at 50 days reached $45.43, while 200 days put it at $35.63.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 34.70, which if violated will result in even more drops to 30.75. On the upside, there is a resistance level at 41.21. A further resistance level may holdings at 43.77. The Relative Strength Index (RSI) on the 14-day chart is 25.70, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.66%. Stochastics %K at 20.90% indicates the stock is a holding.
How much short interest is there in Protagonist Therapeutics Inc?
A steep rise in short interest was recorded in Protagonist Therapeutics Inc stocks on 2024-10-31, dropping by -0.24 million shares to a total of 3.28 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.52 million shares. There was a decline of -7.25%, which implies that there is a negative sentiment for the stock.
